LatinaBA is a Contract Research Organization with more than 15 years in the market offering services in Latin America. We are experts in the region and have extensive experience conducting all phases of clinical trials including research with Medical Devices, Observational and RWE studies and Clinical Trial Oversight.
LAT RESEARCH SRL
LAT Research is a privately held Contract Research Organization (CRO), founded in 2010 and an active member of the Argentine Chamber of Clinical Research Organizations (CAOIC). We specialize in providing regulatory-compliant, high-quality clinical research services across Latin America. We partner with global sponsors to facilitate clinical development in alignment with international regulatory standards, including those of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and ANMAT (Argentina’s National Administration of Drugs, Food and Medical Technology). ________________________________________ Clinical Trial Experience Since its establishment, our clinical operations team has supported more than 70 clinical trials across multiple phases and therapeutic areas. Our proven track record includes • Orphan and rare diseases • Translational medicine • Neglected and infectious diseases • Studies involving vulnerable or underserved populations Our operational strategies are aligned with ICH-GCP guidelines and tailored to meet both regional and global regulatory expectations. Regional Capabilities LAT Research is led by a team of senior physicians and industry experts with over 25 years of experience in clinical development and regulatory affairs. We maintain dedicated teams across Latin America, allowing for • Efficient site selection and patient recruitment • Deep understanding of local regulatory frameworks (FDA, EMA, ANMAT, INVIMA, COFEPRIS, among others) • Seamless coordination of multicenter studies Comprehensive Services for Sponsors We offer full-service CRO capabilities from early-phase trials through to registration and post-marketing studies, including: • Clinical development • Regulatory strategy and submissions • Site management and monitoring • Data management and biostatistics • Pharmacovigilance • Quality assurance and audit support Why Global Sponsors Choose LAT Research • Expertise in regulatory navigation across Latin American countries • Proven performance in complex, multicenter studies • Strong investigator networks and KOL relationships • Flexibility and client-centered project delivery • Commitment to quality, ethics, and operational excellence
Laboratorios Richmond SACIF
Richmond CDMO fully-integrated biotech services from development to supply chain. Single-use upstream and downstream GMP processing Mammalian cell culture platform for recombinant proteins and adenoviruses Fully automated filling and packaging lines for vials, pfs and cartridges. | We are a regional pharmaceutical company and CDMO based in Argentina that develops and produces medicines using cutting-edge technology. Our portfolio includes generic products, biosimilars, and technology licenses and transfers from key countries. We also create innovative solutions by combining different active ingredients in a single tablet and developing user-friendly packaging that facilitates therapeutic adherence and significantly improves our patients’ quality of life. Biotechnology Plant: A unit dedicated to the production of 100% of the production cycle for both vaccines and complex biotechnological products. As CDMO we offer our development and production capacity for biologicals, including vaccines and biosimilars. The plant has over 10,000 m2 dedicated to the production of biological active ingredients and finished products, it includes a GMP-compliant pilot plant and QC laboratories. The plant is equipped with single-use technology (upto 1000-L bioprocess) and has completely independent F&F areas distributed across two lines, providing maximum flexibility. The total estimated capacity will be approximately 80 million vials and 28 million syringes per year.
LABORATORIOS CASASCO
Laboratorios Casasco is a pharmaceutical manufacturing company headquartered in Buenos Aires, Argentina. It was founded in 1876, making it one of the country’s oldest pharmaceutical companies. Our mission is to advance global health and well-being by developing pharmaceutical products of the highest quality, grounded in scientific excellence and ethical integrity. Our portfolio includes cardiovascular health, Urology, Neurology and psychiatry, Immunology, Endocrinology (e.g., diabetes), Anti-infectives, Gastrointestinal treatments, Women’s health, and preventive medicine. Born in the 19th century, walked along the 20th century, and entered the 21st century as an enduring Argentine endeavor through the centuries.
INSUD
Insud (Innovation, Sustainability and Development) is a business ecosystem with global reach that develops innovative solutions with a sustainability commitment to help improve fundamental aspects of human life: health, food and nutrition, energy and culture. In the pharmaceutical/biotechnology field, it operates throughout the value chain, providing its specialized knowledge in scientific research, development, manufacturing, sales and marketing of a wide range of products for human health. Insud Argentina stands out by developing monoclonal antibodies, vaccines and polyclonal immunotherapeutic sera. Nowadays we are developing alternative proteins, together with biotech startups. | Insud is a highly diversified group with global presence that operates across the entire pharmaceutical/biotech value chain, delivering specialized expertise in scientific research, development, manufacturing, sales and marketing of a wide range of compounds for human care. Insud Argentina stands out by developing monoclonal antibodies, vaccines and immunotherapeutic polyclonal sera.
Camara Argentina de Biotecnologia
CAB was founded in 2011 with the aim of contributing to a public-private policy in biotechnology and the development of the sector, from a global perspective that integrates from research and development, to the production, marketing and export of biotechnological products. It brings together leading companies in various areas such as human health, food industry, animal and plant health, diagnostics, agricultural industry, forestry, industrial inputs and biofuels. The Argentine Chamber of Biotechnology (CAB) seeks to enhance Argentina’s leadership role in biotechnology at the regional level by contributing to the coordination of valuable joint work between actors from various sectors, with the aim of strengthening the country’s position in this field. | Founded in 2011, the Argentine Chamber of Biotechnology (CAB) is a non-profit civil association that brings together 38 leading companies with national presence. These companies allocate 4.6% of their sales to R&D and engage over 1,000 scientists. Its mission is to strengthen the biotechnology sector in Argentina by fostering links among companies, startups, academia, and public institutions, and by promoting sustainable solutions in health, agribusiness, energy, food, and the environment. It aims to position the country as a regional and global leader in biotechnology innovation. Its vision is to consolidate a robust biotechnology ecosystem based on innovation, collaboration, and excellence, with a strong international outlook and a firm commitment to sustainability. Objectives: ● Bring together ecosystem stakeholders to drive innovation. ● Promote the training of specialized talent. ● Encourage the sustainable use of biotechnology. ● Position Argentina as a regional leader. ● Support the internationalization of the sector. The chamber actively participates in public policy, represents companies before national and international organizations, and promotes the socio-economic impact of the sector. It also organizes seminars, training sessions, workshops, and networking spaces. The Chamber supports startups and fosters technology transfer, strengthening the global integration of Argentine biotechnology. Since its inception, it has brought together companies that apply biotechnology in agribusiness, human and animal health, industry, environment, and food. The chamber organizes BioArgentina (https://www.cabiotec.com.ar/bio-argentina) BioArgentina is the country’s main annual meeting for science, innovation, and biotechnology. For over a decade, BioArgentina has established itself as a strategic event for the national and regional biotechnology ecosystem. In previous editions, it has taken place in various cities across Argentina—such as Buenos Aires, Rosario, Córdoba, Mendoza, and Mar del Plata—gathering scientists, entrepreneurs, companies, investors, and policymakers to foster collaboration and business development in the sector. The event features an intensive program of talks, panels, and networking spaces that connect leading companies with researchers and young professionals. The BioBusiness Matchmaking Rounds (BioRondas de Negocios) generate strategic alliances and high-value networking opportunities. Organized by CAB and drawing close to a thousand attendees annually, the event positions biotechnology as a driver of economic growth, integrating actors from the private sector, academia, and government. It also promotes public policies, access to funding, and international integration. Startups are also part of the chamber, “CAB Startup” Launched in 2020, CAB Startup now includes 109 startups and 3 accelerators from Argentina, Uruguay, Chile, Brazil, Colombia, and Mexico. It offers mentoring, institutional representation, and networking opportunities with leading companies, facilitating technology transfer and the development of innovative solutions. This platform strengthens public-private collaboration and positions Argentina as a regional leader in emerging biotechnology.
BIOPROFARMA BAGO
For more than 15 years Bioprofarma Bagó has been positioned as a laboratory specialized in high-complex treatments with different therapeutical areas and with a wide-range portfolio of health care products. To be part of Bagó Group, with its development, strength and prestige, endorses our new identity. Our history begins in 2003, when Bagó Group became interested in cancer and biotechnology areas. Since that moment, and aiming to offer therapeutic solutions with proven efficacy and quality, our company has been expanding and improving its portfolio with new molecules in order to enlarge the physicians´ treatment decisions for their patients. Currently we have 56 products and 88 approved presentations, which are registered in Argentina, and many of them are also approved by the regulatory agencies in Latin America, Southeast Asia and French speaking Africa. Our portfolio is mainly focused on Hematology, Oncology, Urology, Neurology and Rare Diseases. Besides the products developed in our own laboratory, we have received licenses of multinational companies which have entrusted us the promotion and distribution of their products in Argentina. Focused on being a leader company in medicines for special pathologies in the region, we have recently finished the construction of a new pharmaceutical plant in Argentina. This plant will have two specialized production lines: one for injectable medications (both liquid and lyophilized), and the other one for the development of solid oral products. This new plant will be among the most modern of the country, in compliance not only with the ANMAT standards, but also with the most demanding regulatory authorities in the region. Our purpose is to expand our current exports far beyond our 17 destinations and to reach new territories. We are completely aware that behind each medicine that Bioprofarma Bagó supplies to the market, there is a hope of recovery and an improvement for the quality of a person´s life. This awareness, that demands and commits us to the whole society, is the inspiration and the motivation for meeting better therapeutical alternatives. The importance we give to ensure quality, in compliance with good manufacturing practices, was and will be our basis as a company. Bioprofarma Bagó grows, evolves and is transformed to go beyond the limits of science through safe, efficient and innovative solutions. The constant evolution identifies us and makes us unique.